Department of Hematology and Oncology Sciences L. A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Colorectal Dis. 2011 May;13(5):542-8. doi: 10.1111/j.1463-1318.2010.02212.x.
The aim of the study was to detect and compare the epidermal growth factor receptor (EGFr) content using different methods, to establish whether the quantitative detection and functional study of EGFr in colorectal cancer, using methods other than immunohistochemistry (IHC), are appropriate.
Analysis of EGFr by IHC was performed in 230 colorectal cancer patients using monoclonal anti-EGFr. Total and activated EGFr (pY1068) contents were determined in 92 patients and real-time PCR, to determine the level of EGFr messenger RNA, was carried out in 60 patients.
There was no association between EGFr IHC groups and the mean total EGFr levels measured using ELISA.
The study shows that the results of different EGFr detection methods do not correlate with each other. Hence, the real role of EGFr in colorectal cancer remains unsettled. Clinically, the receptor itself does not seem to be important and it would be better to focus on EGFr signalling in downstream pathways.
本研究旨在通过不同方法检测并比较表皮生长因子受体（EGFr）含量，以确定是否可以采用免疫组织化学（IHC）以外的方法对结直肠癌 EGFr 进行定量检测和功能研究。
采用单克隆抗 EGFr 对 230 例结直肠癌患者进行 EGFr 的 IHC 分析。对 92 例患者进行总 EGFr（pY1068）和激活 EGFr（pY1068）含量的检测，对 60 例患者进行实时 PCR 以确定 EGFr 信使 RNA 的水平。
EGFr IHC 组与 ELISA 检测的平均总 EGFr 水平之间无相关性。
该研究表明，不同 EGFr 检测方法的结果彼此不相关。因此，EGFr 在结直肠癌中的实际作用仍未确定。临床上，受体本身似乎并不重要，最好关注下游信号通路中的 EGFr 信号。
